---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028184"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T07:53:09.037162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M

## Summary
- Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.
- Tightened FY 2022 revenue guidance to $400-410M from prior range.
- Cash and investments $401.2M at Sept 30, up from $382M at June 30.
- Operating expenses $69.8M (+16.5% YoY) on clinical and commercial expansion.
- Enrolling pivotal Phase 3 ROSELLA trial in ovarian cancer; GRATITUDE AIWG data expected Q4 2022.

## SEC filing metadata
- accession: 0001628280-22-028184
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/0001628280-22-028184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/cort-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028184
- JSON: https://secwatch.observer/filing/0001628280-22-028184.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028184.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2022 results: revenue $101.7 million, net income $34.6 million, EPS $0.30. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $101.7 million
  - Net income: $34.6 million
  - EPS: $0.30
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue of $101.7 million, compared to $96.1 million in third quarter 2021 • Tightened 2022 revenue guidance of $400 – $410 million • Diluted net income per common share of $0.30, compared to $0.24 in third quarter 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/0001628280-22-028184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.